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Abstract
Background: People with diabetes and comorbid severe mental illness (SMI) form a growing population at risk of
increased mortality and morbidity compared to those with diabetes or SMI alone. There is increasing interest in
interventions that target diabetes in SMI in order to help to improve physical health and reduce the associated
health inequalities. However, there is a lack of consensus about which outcomes are important for this comorbid
population, with trials differing in their focus on physical and mental health. A core outcome set, which includes
outcomes across both conditions that are relevant to patients and other key stakeholders, is needed.
Methods: This study protocol describes methods to develop a core outcome set for use in effectiveness trials of
self-management interventions for adults with comorbid type-2 diabetes and SMI. We will use a modified Delphi
method to identify, rank, and agree core outcomes. This will comprise a two-round online survey and multistakeholder
workshops involving patients and carers, health and social care professionals, health care commissioners, and other
experts (e.g. academic researchers and third sector organisations). We will also select appropriate measurement tools
for each outcome in the proposed core set and identify gaps in measures, where these exist.
Discussion: The proposed core outcome set will provide clear guidance about what outcomes should be measured,
as a minimum, in trials of interventions for people with coexisting type-2 diabetes and SMI, and improve future synthesis
of trial evidence in this area. We will also explore the challenges of using online Delphi methods for this hard-to-reach
population, and examine differences in opinion about which outcomes matter to diverse stakeholder groups.
Trial registration: COMET registration: http://www.comet-initiative.org/studies/details/911. Registered on 1 July 2016
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Background
Severe mental illness (SMI) is a term used to describe ill-
nesses in which psychosis occurs (e.g. schizophrenia,
schizoaffective disorder, and bipolar disorder). Diabetes
is two to three times more common in people with SMI
compared to the general population [1], and is associ-
ated with worse health outcomes [2]. Higher prevalence
and poor management of diabetes is thought to contrib-
ute significantly to the lower life expectancy of people
with SMI [3], which is around 15 years lower than the
general population [4, 5]. Poor diabetes management
leads to complications including heart disease, stroke,
foot ulceration and amputation, eye and kidney disease
[6], many of which can be prevented with better diabetes
care. In England, it is estimated that approximately
50,000 people with SMI also have diabetes [7], a figure
that is expected to grow in line with the growing num-
bers of people with both diabetes and mental illness; re-
cent evidence suggests that prevalence of diabetes is
increasing at a faster rate in people with SMI than in
people without [1].
Various pharmacological and behavioural interventions
to prevent diabetes or to improve its outcomes have
been tested in people with SMI [8–11]. Many of these
target metabolic and cardiovascular risk factors, with the
majority focusing on the metabolic side effects of anti-
psychotic medications, such as olanzapine and clozapine,
which are commonly prescribed in SMI [10]. Interven-
tions typically include physical activity and weight loss
programmes [12, 13]; behaviour change techniques that
seek to promote positive lifestyle changes (e.g. problem
solving and goal setting) [14, 15]; antidiabetic and weight
loss medications [16, 17]; switching to, or adding, an
antipsychotic medication associated with fewer meta-
bolic side effects [18, 19]; and other drugs (e.g. hypnotics
and antiepileptic medications) [20, 21], which are
thought to alter metabolic functioning, anthropological
markers, or other important risk factors (e.g. blood pres-
sure, lipid levels).
While few studies have focused specifically on people
with coexisting diabetes and SMI [22], several published
trials include people with both conditions, and there is a
growing interest in developing interventions targeting
this comorbidity [23]. Systematic reviews of the evidence
consistently find incomplete reporting of outcomes and
poor study quality [8–11], due in part to the lack of con-
sensus about what outcomes are important for diabetes
comorbid with SMI. This makes it difficult to build an
evidence base about what works in this population, with
studies differing in their focus on physical and mental
health, and their selection of diabetes-related outcomes.
For example, in a meta-analysis of lifestyle interventions
for people with SMI [11], only eight of 25 included
studies measured the effect on glycaemic parameters
and only four measured depressive symptoms, despite
the fact that diabetes is associated with increased depres-
sion and distress [24]. Another systematic review of
pharmacological and behavioural interventions reported
similar results, with only eight of 33 studies measuring
glucose control strategies [9]. This makes it difficult to
pool results of different studies and draw conclusions
about how to improve diabetes outcomes.
A standardized set of outcomes for interventions
targeting comorbid diabetes and SMI is, therefore, re-
quired. Core outcome sets, defined as ‘an agreed stan-
dardized collection of outcomes … which should be
measured and reported in all trials for a specific clinical
area’ [25] have already been developed for several condi-
tions and interventions [26]. As well as offering the
potential to reduce outcome reporting bias in trials and
to enable better aggregation of results across multiple
studies, a core outcome set aims to include outcomes
that are important to all relevant stakeholders, such as
patients, carers, health care professionals, and commis-
sioners [25], and will, therefore, include outcomes beyond
purely clinical measurements (e.g. patient-reported out-
comes or reports from caregivers).
Previous studies have employed various approaches to
determine which outcomes to consider for inclusion in a
core outcome set, (e.g. systematic reviews and qualitative
inquiry), and to reach consensus about the outcomes
that are most important (e.g. ranking methods such as
Delphi and Nominal Ranking Technique) [26]. A recent
systematic review that aimed to increase understanding
about the methods used in the growing number of core
outcome set studies found no completed studies relevant
to either the SMI or diabetes populations [26]. Five per-
tinent studies are currently registered on the Core
Outcome Measures in Effectiveness Trials (COMET)
database [27]. There are two ongoing studies aiming to
develop a core outcome set: one for the treatment of
type-2 diabetes in adults [28], and the other for people
with schizophrenia and bipolar disorder living in the
community [29]. Two studies have focused on identify-
ing outcomes already employed in trials. One examined
the first 10,000 trials on the Cochrane Schizophrenia
Group’s Register and found that 2194 instruments were
used to measure outcomes of 1940 different interven-
tions [30]. Another examined whether diabetes trials in-
cluded outcomes important to people with diabetes such
as death and quality of life; 201 of 436 trials included
them as a primary or secondary outcome [31]. The
final study sought patient preferences about diabetes
outcomes. Reducing risk of death was selected as the
most important outcome (followed by reducing glyco-
sylated haemoglobin (HbA1c)), but preventing kidney
failure and need for dialysis was the most frequently
endorsed [32].
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Other work relevant to identifying important diabetes
outcomes includes the American Association of Diabetes
Educators’ (AADE) Diabetes Education Outcomes Project,
which provides a framework for benchmarking and uni-
versal measurement of diabetes self-management educa-
tion (DSME) interventions [33]. The DSME Outcomes
Continuum includes immediate (e.g. knowledge, skills);
intermediate (e.g. healthy eating, physical activity); post-
intermediate (e.g. HbA1c, Body Mass Index (BMI)); and
long-term outcomes (e.g. quality of life), which, while
particularly pertinent for DSME programmes, are also
relevant to self-management of other long-term condi-
tions. Knowledge and skills, improved quality of life, and
biomedical markers were also highlighted in a systematic
review of stakeholder views of self-management outcomes
[34]. The review identified other important outcomes as
well, including independence, relationships with health
care providers, wellbeing, and managing stress. Addition-
ally, the review highlighted a lack of consensus between
people with diabetes, carers, and health professionals.
While these studies help to inform the identification
of outcomes that are relevant for people with either
SMI or diabetes, simply combining outcomes for dia-
betes and SMI may not capture what is most important
for people living with both conditions together [35].
Self-management is the cornerstone of good diabetes
management [36]. However, people with SMI have mo-
tivational, cognitive, and psychological deficits that may
impact on their ability to manage their diabetes. Out-
comes of self-management interventions in this popula-
tion may, therefore, be different from those without
SMI. Additionally, diabetes is associated with an in-
creased risk of depression and distress, which is an es-
pecially important consideration for people who already
have an underlying mental illness [24]. Coexisting
physical and mental illness is likely to affect people in
ways that are different from having one condition
alone, including the medication they take, and how
they interact with health services and manage their
health on a daily basis [37]. Relevant outcomes are,
therefore, likely to cover multiple health domains, in-
cluding functional, physical, cognitive, and emotional.
Our group is currently undertaking a programme of
research to develop and evaluate a DSME programme
tailored for people with coexisting type-2 diabetes and
SMI, the ‘Diabetes and Mental Illness – Improving Out-
comes and Services (DIAMONDS)’ programme. No
DSME intervention has been tested previously in this
population, and to date only one published randomised
controlled trial has specifically targeted people with both
diabetes and SMI [38]. To support the DIAMONDS
programme of work, a necessary first step is to develop
a core outcome set for DSME interventions targeting
people with coexisting type-2 diabetes and SMI. The
purpose is to ensure that evidence about what works for
this population can be developed and aggregated to offer
meaningful conclusions for patients, carers, clinicians,
policy-makers, and health care commissioners.
Aims and objectives
This study aims to develop a core outcome set for self-
management interventions targeting adults (age 18 years
and over) with coexisting type-2 diabetes and SMI,
which captures important domains and is acceptable to
people living with both of these conditions and for those
who support them.
The study has four objectives, to:
1. Identify potential outcomes to consider from existing
evidence and through a multistakeholder workshop
and service user panel meeting
2. Rank outcomes to include in the core outcome set
through a two-round online survey with all relevant
stakeholders
3. Agree which outcomes to include in the set during a
multistakeholder consensus workshop
4. Select appropriate measurement tools for each
outcome in the core outcome set through
systematically searching the trials literature, and
identify gaps in measures where these exist
Methods
Overview
Using a modified Delphi method, this study will employ
a three-stage process to (1) Identify, (2) Rank, and (3)
Agree core outcomes. The study will comprise a two-
round e-Delphi survey and multistakeholder workshops
involving patients and carers, clinical professionals, health
care commissioners, and other experts (e.g. academic re-
searchers and third sector organisations). In a fourth stage,
the study will review existing trials literature to (4) Select
appropriate measurement tools for each outcome in the
core outcome set and identify gaps where these exist.
This study draws on learning from the OMERACT
(Outcome Measures for Rheumatology) collaboration [39];
the COMET Initiative [27]; and a review of methods
employed in studies of this type [26], to select appropriate
consensus methods for developing the core outcome set,
and for ensuring meaningful input from patients and
carers. The study will be registered on the COMET website
to alert others to our work, and to share learning
from our study.
Step 1: Identify outcomes
1. Identify potential outcomes to consider from existing
evidence and through a multistakeholder workshop
and service user panel meeting
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Review of existing evidence
We will identify systematic reviews of trials and other
experimental studies in people with diabetes and SMI
and extract information about outcome measures used
in included studies. Only outcomes measured in large
studies (more than 20 participants) will be selected, as
we seek to identify those practicable to measure in a
large trial. We will also incorporate outcomes from the
AADE DSME Outcomes Continuum [33] and the sys-
tematic review of self-management outcomes that are
important to people living with the conditions, carers,
and health professionals [34], to form a list of potential
outcomes for stakeholders to review.
Multistakeholder workshop and service user panel meeting
A multistakeholder workshop will be held, attended by
health care professionals and other relevant stakeholders
as well as the research group (n = 20). Participants will
be asked to work in small groups to identify outcomes
that are potentially relevant and important. Findings
from the review of existing evidence will then be pre-
sented, followed by further small group work to identify
duplicate and overlapping outcomes, and to develop a
final ‘long-list’ of potential outcomes to include in a core
outcome set. Following the workshop, the long-list will
be presented to a panel of service users with diabetes
and SMI and their carers (the DIAMONDS PPI Panel),
who will also be given an opportunity to add new out-
comes that have not already been identified.
Step 2: Rank outcomes
2. Rank outcomes to include in the core outcome set
through a two-round online survey with all relevant
stakeholders
An online survey will be administered to determine
which outcomes in the list developed in step 1 are im-
portant to different stakeholder groups. The purpose of
the Delphi study is to reduce the list of potential out-
comes to a smaller core set based on the collated re-
sponses of participants, but also taking into account the
potentially differing views between diverse stakeholder
groups and enabling participants to change their views
as part of developing a group consensus [40]. Unlike
methods like Nominal Ranking Technique, a Delphi
study does not require participants to interact to reach a
consensus, and instead provides all participants with an
equal opportunity to input directly and anonymously.
This study draws on methods employed in other rele-
vant studies [29, 41, 42], and also takes into account the
potential burden on patient and health and social care
professional participants of taking part in a study involving
several stages. Although potential participants will be
encouraged to take part in the online survey, a paper
version will be available to ensure that patients and carers
in particular are able to take part.
Participants
The following stakeholders will be purposively sampled to
ensure good representation across the different groups:
1. Adults with coexisting SMI (which for this study
we define as illnesses in which psychosis occurs
including schizophrenia, schizoaffective disorder,
bipolar disorder and severe depression) and type-2
diabetes living in the community (n = 5–10)
2. Carers/supporters (expected to be a spouse, other
family member or close friend providing regular
care or support to a person with SMI and diabetes)
(n = 5–10)
3. Health and social care staff (to include GPs,
diabetologists, psychiatrists, psychologists, nurses,
mental health care co-ordinators, social workers,
and other staff supporting this patient group)
(n = 15–20)
4. Health service managers and commissioners
(n = 5–10)
5. Academic experts in diabetes, mental illness,
primary care and outcome measurement
(n = 15–25)
Sample sizes vary across Delphi studies; based on pre-
vious work [26] and taking into account the small target
patient population, this study will aim to recruit between
50 and 75 participants to the first round. To ensure
good representation of patients, the DIAMONDS PPI
Panel will also be invited to take part in the Delphi study
(n = 5–10).
Recruitment
Patients and carers will be recruited through Commu-
nity Mental Health Teams (CMHTs) based in participat-
ing mental health NHS trusts in one region of England,
using care co-ordinators (mental health nurses, occupa-
tional therapists, social workers, and support workers
who case manage individuals with SMI) to identify and
invite eligible patients on their caseloads whom they as-
sess as having capacity to consent. Other participants
will be recruited through NHS and third sector organisa-
tions involved in the wider research programme. Partici-
pants will be informed that there will be two stages in
the survey. We will also seek endorsement for this work
from professional organisations to assist with recruit-
ment for the Delphi study and also adoption of the core
outcome set into research and practice.
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Delphi round-1 survey
The survey will be designed and administered using
Qualtrics [43], a secure web-based survey tool used suc-
cessfully in research with mental health service users
[44] and staff supporting people with SMI [45]. All par-
ticipants will be assigned a unique identifier and basic
demographics will be collected to assist with the analysis
and collation of responses. During round 1, all potential
outcomes will be presented to participants, who will be
asked to rate the importance of each outcome on a scale
with anchors ranging from 1, being not important to 9,
being of critical importance.
Using free-text boxes participants will have an oppor-
tunity to provide written feedback about their choices,
and to suggest additional outcomes that they believe
are important. Participants will be given 4 weeks to
complete the survey – response rates will be monitored
throughout to ensure good representation across the
participant groups. If a stakeholder group is under-
represented in the survey (fewer than five participants),
a further attempt to recruit additional participants will
be made.
Round-1 analysis
Data will be analysed by stakeholder group and for all
participants together. For each outcome, the number of
respondents and distribution of scores will be sum-
marised and analysed. The proportion of participants
scoring 1–3, 4–6, and 7–9 for each outcome will also be
calculated. Text data provided by participants in the free
text fields will be reviewed by the research team to iden-
tify new outcomes to include in round 2 of the Delphi
study survey and delete or merge duplicate or overlap-
ping concepts.
Delphi round-2 survey
Participants from round 1 will be invited to participate
in round 2. As outlined above, we will take precautions
to reduce dropout for this second stage, including clearly
informing participants of the two stages in the survey. If
respondents from the first round cannot participate in
the second, we will seek to recruit additional participants
from the same stakeholder group if they are under-
represented.
Participants will be presented with the following find-
ings from round 1: ranking of outcomes for the whole
group, ranking of outcomes for their own stakeholder
group, and their individual scores. Participants will then
be asked to rate each outcome again using the same
Likert scale so that participants can adjust their scores,
and to allow for comparisons between round 1 and
round 2.
Round-2 analysis
Drawing on consensus methods used in similar studies
[26], data will be analysed by stakeholder group and for
the whole group to determine for each outcome, the
percentage of respondents who have scored 1–3, 4–6,
and 7–9.
Each outcome will be categorised as one of the
following:
(a) ‘Consensus In’ (i.e. the outcome should be included
in the core outcome set): more than 70% of
participants score the outcome as 7–9 (important)
and fewer than 25% score the outcome as 1–3
(not important)
(b)‘Consensus Out’ (i.e. the outcome should not be
included in the core outcome set): more than 70%
score the outcome as 1–3 (not important) and
fewer than 15% score the outcome as 7–9
(important)
(c) ‘No Consensus’ (i.e. there is no strong consensus
about the importance of the outcome): any other
distribution of scores
We will analyse in detail the consistency of these re-
sults within groups as well as across groups to make
statements about the relevance of the outcomes across
all participating stakeholders, and to ensure that no
voices remain unheard and that minority stakeholders
are not over-ruled by the majority.
Step 3: Agree outcomes
3. Agree which outcomes to include in the core
outcome set during a multistakeholder consensus
workshop
Delphi consensus workshop
The detailed results from the survey will be presented at
a Delphi workshop to be attended by people with SMI
and type-2 diabetes, carers, health and social care pro-
fessionals, health care commissioners, and other relevant
stakeholders as well as the research group (n = 20). We
anticipate that patients may prioritise outcomes in the
Delphi study that practitioners or commissioners may
not, and vice versa. It is, therefore, important that we in-
clude the views of all relevant stakeholders in this work-
shop to reach a decision about outcomes for which
there was no clear consensus in the Delphi study. To en-
sure that we have meaningful input across participant
groups, people participating in the Delphi study will be
invited to attend the workshop, and for groups that are
difficult to recruit for this part of the study we will make
efforts to seek their views in advance of the workshop.
We will also consult with the DIAMONDS PPI Panel
Taylor et al. Trials  (2017) 18:70 Page 5 of 9
separately prior to the workshop so that their views
about the results of the Delphi study can be incorpo-
rated into the final selection process.
The purpose of the consensus workshop is to agree a
final set of outcomes for the core outcome set, using the
detailed findings from the survey. This is a key element
of the modified Delphi method which combines self-
administered questionnaires and physical meetings [46].
All outcomes will be discussed. Each ‘Consensus In’ out-
come will be discussed to ensure that it is measurable
and feasible to include in the core set. Each ‘Consensus
Out’ and ‘No Consensus’ outcome will be assessed to en-
sure that key outcomes that are commonly used to make
policy or commissioning decisions about adoption have
not been excluded from the set (e.g. outcomes used for
cost-effectiveness analyses). The detailed results for each
‘No Consensus’ outcome will be discussed to determine
whether they should be included in the final set. To en-
sure that there is no duplication in the final proposed
set, each outcome will be discussed to ensure that it
relates to a distinct construct and to start identifying
existing measurement tools (and key validation studies
of measurement tools) in preparation for step 4.
Finally, workshop participants will be asked to select
the two outcomes that they consider most important to
assess for diabetes and SMI populations from the pro-
posed core outcome set.
Step 4: Identify instruments to measure outcomes
4. Select appropriate measurement tools for each
outcome in the core outcome set, and identify
gaps in measures where these exist
We will adopt a pragmatic approach to identify measure-
ment tools as follows:
1. Discussion during the final consensus workshop to
identify commonly used tools that are well validated
(e.g. some outcomes will be measured consistently
with one tool which has been validated in a key
paper). Key papers for identified outcomes will be
assessed against the COnsensus-based Standards for
the selection of health Measurement INstruments
(COSMIN) Checklist [47] which uses a rating scale
to assess the quality of measurement properties
2. For the remaining outcomes, a systematic review of
published studies on the properties of all available
measurement instruments that aim to measure the
particular construct will be conducted. Study criteria
and methods for the systematic review will be
adapted depending on the final core outcome set.
A search strategy comprising text words and index
terms will be developed using a search filter for
outcome measure properties [48] and search terms
for each of the outcomes in the final core outcome
set. Results identified from the search will be
screened by two researchers independently, first
by title and abstract to remove irrelevant studies,
and second by full text to identify all papers that
provide details of potentially matching measurement
tools. The measurement and psychometric
properties of all potentially matching tools will
be assessed using the COSMIN Checklist [47]
before selecting which tools to include for
outcomes in the core outcome set
Outcomes for which no matching validated measure-
ment tool is identified will be highlighted in the review
to inform future research priorities.
Discussion
To ensure that evidence about what works for particular
populations can inform policy and practice and improve
the quality and effectiveness of health care, evaluation
research must measure what matters to people living
with the condition and those who support them and
commission health services, as well as to researchers.
Developing core outcome sets using appropriately
adapted consensus and trials literature review methods
facilitates this, and helps to increase consistency of
measurement in future research thereby enhancing the
potential to combine trials for evidence synthesis. The
proposed core outcome set for this study will provide
clear guidance about what outcomes should be mea-
sured, as a minimum, in trials of self-management inter-
ventions for people with coexisting type-2 diabetes and
SMI, and help to improve future aggregation of trial evi-
dence in this area.
There are several challenges that we are likely to en-
counter. First, the study risks not including representa-
tion across stakeholder groups, in particular patients and
carers. People with SMI are a hard-to-reach group; how-
ever, working with mental health care co-ordinators to
identify and recruit participants is an approach used suc-
cessfully in other research [49]. People with SMI are also
less likely than the general population to have regular
access to the Internet [50], which is a prerequisite for
completing an online survey. The Delphi study will
therefore, as needed, be administered by post, telephone
or in person, as well as online. To promote continued
engagement we will endeavour to make sure that the
survey is easy to complete by piloting this with the DIA-
MONDS PPI Panel, and we will recruit additional partic-
ipants if we experience dropout in this or other
stakeholder groups. There is a risk that during the con-
sensus workshop, the voice of patients and carers is not
present or is under-represented. The DIAMONDS PPI
Taylor et al. Trials  (2017) 18:70 Page 6 of 9
Panel members have expressed their desire to meet sep-
arately and to have their views presented at the work-
shop instead of attending in person. To ensure that
other patient and carer participants are able to contribute
to this process, we will use a skilled facilitator during the
workshop and also provide them with an opportunity to
meet separately with a researcher if they prefer.
Second, we may find differences in opinion between
diverse stakeholder groups as they seek to achieve con-
sensus about which outcomes are important. Core out-
come sets are a relatively new construct in research, and
methods for reaching consensus are evolving as studies
begin to reflect on their successes and limitations [25].
A key feature of the Delphi survey is building consensus
by including more than one round, and sharing the re-
sults of each round with participants, so that these can
inform the choices that individuals subsequently make.
However, there are likely to be multiple outcomes that
do not reach consensus, and the modified Delphi
method provides an opportunity to resolve areas of dis-
agreement between different stakeholder groups and en-
sure that all groups are represented in this process.
There are examples in the trials literature where out-
comes that are discarded by consensus are included in a
core outcome set or vice versa [51]. While this may be
contentious, a flexible and pragmatic approach allows
for decisions to be taken which are based on the consen-
sus opinion but also take account of the necessity to in-
clude measurable and appropriate outcomes.
A flexible approach that acknowledges the expert in
the final selection process also helps to address a third
challenge, which all research of this type will face in the
context of rapidly developing medical technologies and
expanding psychometric and epidemiological evidence:
the accuracy and stability of the concepts guiding our re-
search (SMI and diabetes). For example, current research
into the nature of SMI questions the meaningfulness of
existing diagnostic categories, both aetiologically [52, 53]
and phenomenologically [54]. Thus, the appropriateness
of grouping together SMI conditions that display similar
and overlapping genetic aetiology and symptomatology,
but have different illness trajectories and treatments, con-
tinues to be debated [53]. In diabetes, although supporting
self-management has been the cornerstone of good dia-
betes care for many years, it is a multidimensional concept
that is individualised by those living with diabetes and,
therefore, challenging to measure reliably [55, 56]. Con-
cerns about increasing prevalence of diabetes and associ-
ated costs are fuelling the development of new treatments
and therapies, which introduces a slightly different set of
questions about the management of diabetes and the po-
tential outcomes that capture this.
A fourth challenge relates to patient-reported outcomes,
which are commonly used to evaluate the effectiveness of
interventions. Psychometric assessments of these have
shown that such measures overlap in content [57], and
the incremental value of using multiple measures might,
therefore, be questionable [58]. While the development of
these measures is informed and partly motivated by their
value as an accepted outcome criterion in care and trials
[59], the pressure on researchers to provide evidence on
the mechanisms that drive change in an intervention has
risen [60]. This complex landscape necessitates detailed
reviews of outcome assessment strategies as well as so-
phisticated strategies to define informative, relevant and
sufficiently independent sets of outcome criteria. To as-
sess this, potential outcome measures can be categorised
according to their functional relationship in an interven-
tion, in other words to differentiate whether an outcome
measure could serve as an immediate outcome of the
intervention itself (e.g., content learned); whether it is a
mediator that is meant to change a primary or distal out-
come (e.g., self-management skills); or whether it could
serve as a primary outcome in a trial (e.g., measures of gly-
caemic control and/or psychological distress). This exer-
cise could also draw on existing frameworks such as the
DSME Outcomes Continuum [33] and standardised
approaches for the evaluation of interventions [61].
Finally, there are challenges to ensuring that the core
outcome set we develop is feasible to implement and ac-
cessible to those involved in research in this area. It is
quite possible that the core outcome set will include out-
comes for which we identify no appropriate measure-
ment tool, or one that has not been adequately
validated. If this occurs, we will seek funding to carry
out this work or work in collaboration with others to
validate tools that already exist. Historically, research
has been poor at disseminating to different audiences
and translating evidence into practice [62]. To ensure
that the core outcome set we develop is accessible, we
will update the COMET website in a timely manner, and
make sure that the core outcome set is publicly available
and disseminated through our mental health and dia-
betes research and practice networks.
Study status
At the time of manuscript submission the status of the
core outcome set study is ongoing. Participant recruit-
ment for the Delphi study has not yet commenced.
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